Genedata Bioprocess Offers Out-of-the-Box Integration with ambr Bioreactors
Experimental data from ambr15 and ambr250 bioreactors are now directly captured and integrated into the Genedata Bioprocess workflow management system
October 2, 2018
Genedata, a leading provider of advanced software solutions for biopharmaceutical R&D, today announced a new out-of-the-box integration of the Genedata Bioprocess® platform with the ambr® mini-bioreactor systems from Sartorius, a leading international pharmaceutical and laboratory equipment supplier. This enables the automatic import of raw instrument data into the Genedata Bioprocess platform, where the data can be processed and interpreted in the greater context of all data collected along the complete bioprocess development workflow. The integrations are instrument-specific, versioned, and maintained by Genedata.
ambr systems can now be easily plugged into the Genedata Bioprocess platform, which acts as a data backbone connecting all information from upstream, downstream, formulation, and analytics development units. This new integration capability leads to significant efficiency gains along the full bioprocess workflow.
Genedata Bioprocess is a first-in-class enterprise software solution that enables fully integrated workflow support for large-molecule development and CMC. As an integrated data backbone, it enables the cost-efficient development of next-generation manufacturing processes. Genedata Bioprocess is a modular system that supports the full workflow - from cell line development, upstream process development (USP), downstream process development (DSP), formulation development (FD) and analytical development (AD). The platform scales with highest data volumes and integrates all relevant experimental data, such as from bioreactors, purification instruments, or analytics devices. Genedata Bioprocess has been co-developed with major biopharmaceutical companies over the past five years.
“Our customers can now effortlessly connect Sartorius ambr systems to our Genedata Bioprocess platform. This enables a straight-forward setup of a fully integrated platform,” said Dr. Othmar Pfannes, CEO of Genedata. “The seamless integration between bioprocess instrumentation and Genedata Bioprocess simplifies day-to-day operations, saves time, and lowers our customers’ total cost of ownership. We look forward to expanding our established Ready-to-Run program to other instruments and technologies to further streamline bioprocess development operations.”
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.